Bahija Jallal, Ph.D. has served as a member of Guardant Health’s board of directors since April 2019. Dr. Jallal has been the Chief Executive Officer and Director of Immunocore Limited since January 2019. Prior to Immunocore Limited, from October 2013 to January 2019, Dr. Jallal served as Executive Vice President of AstraZeneca PLC and President of MedImmune, a subsidiary of AstraZeneca, since January 2013. She joined MedImmune in 2006 and held various research and development positions, including Senior Vice President, Research and Development, from 2010 to 2013. She joined MedImmune in 2006 from Chiron Corporation where she served as Vice President of Drug Assessment and Development. Dr. Jallal has authored more than 70 peer-reviewed publications and holds more than 15 patents. She has been a member of the boards of directors of Immunocore Limited since January 2019 and of Anthem, Inc. since February 2018. Additionally, she is a member of the of the Board of Trustees of Johns Hopkins University and UMB Health Sciences Research Park Corporation and Past President of the Association for Women in Science. Dr. Jallal received her Ph.D. in physiology from the University of Pierre & Marie Curie in Paris, France and M.S. in Biology from the Universite de Paris VII in France. She conducted her postdoctoral research at the Max Planck Institute of Biochemistry in Martinsried, Germany.